IRD

#3307
Opus Genetics, Inc. - Common Stock
3.6 9 USD
-0.04%
Market Price
Sektor: Gesundheitswesen
Basis: USD
Gewinnwährung: USD
Tagesspanne
3.69
3.69
Jahresspanne
2.82
5.81
Tagesänderung
-4.16%
Monatliche Änderung
-0.81%
6 month change
-9.56%
Jahresänderung
-0.81%
Vorheriger Schlusskurs
3.8 5
Open
3.6 9
Tief
3.6 9
Hoch
3.6 9
Volumen
59
Vollständige Grafik anzeigen

Financials

Übersicht Finanzbericht Statistik Documents

2026

Current report, Q3 FY2026
Opus Genetics, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Opus Genetics, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Opus Genetics, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Opus Genetics, Inc. quarterly report, Q1 FY2026
10-Q

Opus Genetics, Inc. current report, Q1 FY2026

Full document

Opus Genetics, Inc. Form 8-K Summary

Business Context and Reporting Period

Opus Genetics, Inc. (Nasdaq: IRD) filed this Current Report on Form 8-K on February 13, 2026, regarding a material definitive agreement entered into on the same date. The filing details a private placement of equity securities that closed on February 18, 2026.

Key Financial Metrics

  • Capital Raised: Approximately $25.0 million in aggregate purchase price.
  • Instrument: 7,374,632 shares of Series B Non-Voting Convertible Preferred Stock.
  • Purchase Price: $3.39 per share.
  • Cash Position (Preliminary): $45 million as of December 31, 2025.
  • Pro Forma Cash Position: $70 million as of December 31, 2025, after including Private Placement proceeds.
  • Revenue/Profit/Margins: The filing text does not provide specific values for revenue, profit, cash flow, or margins.
  • Debt/Liquidity: No specific debt figures are provided; liquidity is addressed via the cash balance updates.

Material Changes and Agreements

The Company entered into a Securities Purchase Agreement for the private placement of Series B Preferred Stock. Key terms include:

  • Conversion: Shares are convertible into Common Stock subject to stockholder approval of an increase in authorized shares at the 2026 annual meeting.
  • Registration Rights: The Company must file an initial registration statement for the resale of convertible shares by April 19, 2026.
  • Dividends: Holders receive dividends on an as-if-converted-to-Common Stock basis.
  • Voting Rights: The Series B Preferred Stock is non-voting, except for specific protective provisions regarding adverse changes to their rights.
  • Liquidation Preference: Ranks on parity with Common Stock.

Outlook, Risks, and Management Commentary

Management intends to use the net proceeds to advance gene therapy clinical programs and for working capital and general corporate purposes. The filing includes standard forward-looking statements regarding the consummation of the placement and market conditions. Risks include the uncertainty of stockholder approval for the conversion proposal and the satisfaction of closing conditions.

Investor Verification Checklist

  • Confirm the outcome of the 2026 annual meeting regarding the "Conversion Proposal" to increase authorized Common Stock.
  • Verify the final audited cash balance for the year ended December 31, 2025, as the $45 million figure is preliminary and unaudited.
  • Monitor the filing of the Initial Registration Statement by the April 19, 2026 deadline.
  • Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Certificate of Designation (Exhibit 3.1) for specific beneficial ownership limitations on conversion.